Growth Hormone

Synthetic C-terminal hGH fragment (aa 176-191) for in vitro lipolysis and metabolic signaling research. Stabilized disulfide bond variant.

GHRH analog with Drug Affinity Complex (DAC) technology for extended half-life. Enables sustained GH secretion research with prolonged receptor occupancy (~6-8 days).

Modified GRF(1-29) without DAC conjugation. Shorter half-life GHRH analog for acute pulsatile GH release research and receptor kinetics studies.

Hexapeptide ghrelin receptor (GHSR-1a) agonist for GH secretion and appetite/cytoprotection pathway research. First-generation GHRP with strong GH-releasing potency.

Recombinant 22 kDa human Growth Hormone (somatropin) expressed in E. coli. WHO IU potency assigned. Standard research reagent for GH receptor signaling and IGF-1 axis studies.

Selective pentapeptide GHSR-1a agonist with negligible ACTH/cortisol or prolactin stimulation. Third-generation GHRP with the highest selectivity profile for GH research.

Stabilized GHRH(1-44) analog with trans-3-hexenoic acid N-terminal modification. Precursor for visceral adiposity and somatotropic axis research; closely related to tesamorelin class.

Full-length GHRH(1-44) analog with trans-3-hexenoic acid modification. DPP-IV resistant GHRH analog for visceral adiposity, GH/IGF-1 axis, and lipodystrophy model research.